Recurrent delirium over 12 months predicts dementia: results of the Delirium and Cognitive Impact in Dementia (DECIDE) study

Sarah J. Richardson1, Daniel H. J. Davis2, Blossom C. M. Stephan3, Louise Robinson4, Carol Brayne5, Linda E. Barnes5, John-Paul Taylor1, Stuart G. Parker4, Louise M. Allan6

1Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE4 5PL, UK
2MRC Unit for Lifelong Health and Ageing at UCL, London WC1E 7HB, UK
3Institute of Mental Health, Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham NG7 2TU, UK
4Institute of Population Health Sciences, Faculty of Medical Sciences, Newcastle University, Biomedical Research Building, Newcastle upon Tyne NE4 5PL, UK
5Cambridge Public Health, Cambridge Institute of Public Health, University of Cambridge, Cambridge CB2 0SR, UK
6College of Medicine and Health, South Cloisters, University of Exeter, Exeter EX1 2LU, UK

Address correspondence to: Sarah J. Richardson, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, 3rd floor Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK. Tel: (+44) 0191 2081314. Email: sarah.richardson2@newcastle.ac.uk

Abstract

Background: Delirium is common, distressing and associated with poor outcomes. Previous studies investigating the impact of delirium on cognitive outcomes have been limited by incomplete ascertainment of baseline cognition or lack of prospective delirium assessments. This study quantified the association between delirium and cognitive function over time by prospectively ascertaining delirium in a cohort aged ≥ 65 years in whom baseline cognition had previously been established.

Methods: For 12 months, we assessed participants from the Cognitive Function and Ageing Study II-Newcastle for delirium daily during hospital admissions. At 1-year, we assessed cognitive decline and dementia in those with and without delirium. We evaluated the effect of delirium (including its duration and number of episodes) on cognitive function over time, independently of baseline cognition and illness severity.

Results: Eighty-two of 205 participants recruited developed delirium in hospital (40%). One-year outcome data were available for 173 participants: 18 had a new dementia diagnosis, 38 had died. Delirium was associated with cognitive decline (−1.8 Mini-Mental State Examination points [95% CI –3.5 to –0.2]) and an increased risk of new dementia diagnosis at follow up (OR 8.8 [95% CI 1.9–41.4]). More than one episode and more days with delirium (>5 days) were associated with worse cognitive outcomes.

Conclusions: Delirium increases risk of future cognitive decline and dementia, independent of illness severity and baseline cognition, with more episodes associated with worse cognitive outcomes. Given that delirium has been shown to be preventable in some cases, we propose that delirium is a potentially modifiable risk factor for dementia.

Keywords: delirium, dementia, epidemiology, cohort study, older people

Key points

• Delirium increases risk of future cognitive decline.
• Longer duration, more severe delirium and more episodes of delirium were associated with worse cognitive outcomes.
• Delirium may be a potentially modifiable risk factor for dementia.

Background

Delirium is a sudden onset and fluctuating cognitive disorder, frequently precipitated by acute illness, which specifically affects attention and level of arousal. Delirium is highly distressing and common, affecting 1 in 4 older people in hospital [1,2]. Delirium is independently associated with increased institutionalisation and mortality, longer lengths of hospital stay and more hospital-acquired complications, culminating in substantial additional healthcare costs [2–4]. Delirium is a strong predictor of new-onset dementia as well as acceleration of existing cognitive decline [5–7].

The degree to which delirium is associated with permanent changes in cognition is unclear because most studies (outside specific elective surgical settings) have not assessed prior cognitive function [8–10]. In contrast, the studies that have ascertained prior cognitive function lack reliable delirium measures [11–13]. Therefore, the degree to which baseline cognition and delirium separately or together contribute to cognitive outcomes remains unknown. A further mediator may be acute hospitalisation itself. This has been shown to adversely affect trajectories of cognitive decline, even when delirium has not been specifically ascertained [14–16]. This implies that delirium and/or its acute causes can contribute to the overall burden of dementia.

In order to address the relative contribution of acute and chronic factors in determining subsequent cognitive impairment, the Delirium and Cognitive Impact in Dementia (DECIDE) study aimed to measure the effect of delirium on cognition, independent of illness severity, in a population-based cohort study of incident dementia. A further objective was to quantify the association of other features of delirium, including number of episodes and duration, on cognitive outcomes.

Methods

Population

The DECIDE study is a prospective sample nested within the Cognitive Function and Ageing Study II (CFAS-II) [17,18]. CFAS-II is a large, population-based cohort from three geographical areas in the UK, including Newcastle upon Tyne, measuring prevalence and incidence of dementia [18]. At baseline (2011–2013), 1,751 participants aged ≥ 65 years were recruited to CFAS II-Newcastle sample. Global as well as domain-specific cognitive function was assessed using the Geriatric Mental State, the Cambridge Cognitive Examination and the Mini-Mental State Examination (MMSE). An algorithmic approach to the diagnosis of dementia, depression and anxiety was made using the Automated Geriatric Examination for Computer Assisted Taxonomy, drawing on respondent and observer ratings [18]. The full content of the interviews is available online (http://www.cfas.ac.uk/). All members of CFAS II-Newcastle live within the catchment area of the Newcastle Hospitals NHS Foundation Trust.

Surviving members of CFAS II-Newcastle were contacted by CFAS prior to the start of the DECIDE study. Participants were provided with written information and given the opportunity to opt-out of further contact. All non-objecting members of CFAS-II Newcastle, with or without dementia, were eligible to participate in DECIDE if admitted to the Royal Victoria Infirmary or Freeman Hospital as an emergency or electively between 5 January 2016 and 5 January 2017. We were alerted to admissions by a Recurring Admission Patient Alert on the electronic records system. If the participant themselves lacked capacity, an appropriate personal consultee was requested to provide written confirmation of willingness to participate. Once recruited, participants were seen on each subsequent hospital admission during the study period. Participants were excluded if: they lacked capacity to consent and we were unable to identify or contact an appropriate personal consultee, they were receiving end of life care, they were being isolated for infection control reasons, they were expected to be in hospital for fewer than 24 h.

Exposures

Delirium

Participants were assessed daily throughout their admission. Delirium was ascertained using a standardised procedure based on DSM-5 criteria, combining objective testing of the participant, and information gained from informants (usually nurses, next of kin or clinical records), with structured observations made by two assessors [19]. Disturbance in attention was evaluated using months of the year backwards and digit span, and arousal was recorded using the Observational Scale of Level of Arousal and the modified Richmond Agitation and Sedation Scale [20–22]. Disturbance in cognition was evaluated using 3 item recall, 10 orientation questions, 3 stage commands and any evidence of perceptual disturbances along with observations by the examiner during the interview. Acute onset and fluctuating course, change from baseline and evidence of underlying medical condition were obtained from informant history from nursing staff, next of kin and clinical records. In order to operationalise grades of delirium exposure, we considered three related quantities: (1) number of episodes; (2) total days with delirium; (3) peak delirium severity scores recorded using the Memorial Delirium Assessment Scale (MDAS) [22].

As far as possible, we assessed participants daily during their hospital admission(s) for the presence of delirium. If it was not possible to review participants prospectively at
any particular time point, due to illness, refusal or study capacity, we used a validated tool to retrospectively review the medical records for a diagnosis of delirium [23]. In those participants in whom a diagnosis of delirium was not possible prospectively or was uncertain, study information was sent to an expert consensus panel [LMA, DHJD, SGP]. The vignettes contained a complete copy of the data collection forms for the participant along with all information collected retrospectively from the medical records using the validated tool [23]. Two members of the expert panel [LMA, DHJD] independently reviewed each case and if they disagreed, a third member [SGP] reviewed the case and a majority decision was applied. The panels were tasked with determining whether delirium was present or absent.

Illness severity
Concurrent illness severity was recorded using APACHE II [24].

Other variables
We collected baseline data on recruitment to DECIDE including age, sex, comorbidity (recorded using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G)) and frailty (recorded using the Clinical Frailty Scale) [25,26].

Outcomes
We invited all participants recruited in hospital, with and without delirium, for follow-up 12 months after their most recent hospital discharge. This consisted of a home visit to complete the CFAS II interview for dementia ascertainment [18]. The primary outcomes were dementia status and MMSE score at 12 months after hospital discharge in comparison to baseline cognitive function from CFAS II.

Data collection
All data collection was carried out by the chief investigator [SJR] and a part-time research nurse. At monthly intervals throughout the study, we completed joint assessments of a sample of participants to optimise consistency between assessors. Training to deliver the standardised computerised interview at 1-year follow up was provided by the CFAS team based at University of Cambridge. They also had oversight of on-going quality control, using audio recording of interviews with consenting participants.

Statistical analysis
We evaluated between groups differences using an independent t-test, Kruskall–Wallis test or chi-squared test depending on data type and distribution. We used multiple regression to determine whether delirium was associated with cognitive decline or dementia, independent of baseline cognition and illness severity along with other relevant confounders including age, education, sex, frailty, baseline cognition, time between baseline and follow up interviews and comorbidities. We used multiple regressions to estimate the effect of peak delirium severity, delirium duration and total number of episodes of delirium. We investigated patterns of missing data and delirium cases evaluated by the expert panel in sensitivity analyses. All statistical analyses were performed on STATA Version 15.

Results

Characteristics
Of the 1,751 CFAS II-Newcastle participants with baseline data, 1,328 were surviving and non-objecting at the start of the DECIDE study. During the year of recruitment, 363 (27.3%) were admitted to hospital, 280 were eligible for DECIDE and 205 were recruited (73.2%) (Figure 1). There were no significant differences in baseline characteristics between those who were recruited to DECIDE and those who were not (Supplementary Table 1). Baseline characteristics of DECIDE participants are summarised in Table 1. Ninety six of the 205 participants were readmitted during the study period (46-8%), with a total of 186 readmissions. Median length of stay for all admissions was 5 days (IQR 10-3 days).

Delirium
A total of 82 participants developed delirium in hospital during the study period (40%) and 24 participants had more than one episode of delirium (29%). For those who experienced delirium, the median total number of days with delirium during the study period was 3 days (IQR 6 days). Older age (OR 1.09 per year [95% CI 1.03–1.16]) and lower baseline cognition (OR 0.95 per MMSE point [95% CI 0.91–0.99]) were independently associated with delirium.

Follow-up interviews at 12 months
One hundred and thirty five of 205 participants completed follow up interviews 1 year after hospital admission (65.9%), with 18 participants receiving a new diagnosis of dementia. A total of 38 participants had died prior to follow up (18.5%) and 32 refused follow up (15.6%) (Figure 1). Mean time between participants’ baseline interview, as part of CFAS II-Newcastle, and their follow up interview for DECIDE, was 4.5 years (SD 0.8 years).

The association between delirium and new dementia
An episode of delirium was associated with a markedly increased risk of incident dementia (OR 8.8 [95% CI 1.9–41.4]), independent of illness severity and baseline cognition, as well as age, sex, education, comorbidity, time between interviews and frailty (Table 2). Delirium also independently predicted a decline in MMSE score at follow up interview (β = −1.8 points [95% CI −3.5 to −0.2]) (Table 3). Greater exposure to delirium, in terms of number of episodes, duration and severity, was associated with worse
cognitive outcomes, with greater risk of incident dementia associated with more than 1 episode of delirium (OR 13.9 [95% CI 1.3–151.0]) compared to a single episode (OR 8.6 [95% CI 1.8–41.1]) (Table 2). Additionally, having delirium for more than 5 days during the study period was independently associated with lower MMSE scores at follow up interview ($\beta$ −5.1 points [95% CI −8.1 to 2.1]) compared to 1–5 days with delirium ($\beta$ −1.7 points [−3.4 to −0.1]) (Table 3). More severe delirium was associated with lower MMSE scores at follow up interview ($\beta$ −0.4 points [95% CI −0.6 to −0.2]) and incident dementia (OR 1.3 [95% CI 1.1–1.5]).
episodes of delirium, more days with delirium and greater severity of baseline cognition and illness severity. Further, repeated diagnosis of dementia and cognitive decline, independent shown for the first time that delirium is associated with new cases ascertained via consensus panel requiring a third assessor did not alter the overall results.

**Table 1.** Baseline characteristics of participants

| Variable                                | Total (n = 205) | Delirium (n = 82) | No delirium (n = 123) | P value |
|-----------------------------------------|-----------------|-------------------|-----------------------|---------|
| Age (mean, SD)                          | 82.0 ± 6.5      | 84.7 ± 6.5        | 80.3 ± 5.9            | < 0.001 |
| Sex (% women)                           | 53.2            | 48.8              | 56.1                  | 0.304   |
| ≤10 years in full time education (%)    | 71.2            | 78.1              | 66.7                  | 0.078   |
| Baseline cognition (MMSE) (mean, SD)    | 26.3 ± 3.2      | 24.9 ± 3.7        | 27.3 ± 2.5            | < 0.001 |
| % living in 24 h care                   | 5.9             | 7.3               | 4.9                   | 0.466   |
| Comorbidity score (mean, SD)            | 8.6 ± 4.3       | 10.1 ± 4.2        | 7.6 ± 4.1             | < 0.001 |
| Clinical frailty score (mean, SD)       | 4.3 ± 1.4       | 4.9 ± 1.2         | 3.8 ± 1.4             | < 0.001 |

Demographic data for all DECIDE participants, those who developed delirium during the study period and those who did not develop delirium during this time. Age, accommodation, comorbidity score (total CIRS-G score) and frailty (total Clinical Frailty Scale score) recorded on recruitment to DECIDE.

**Table 2.** Delirium as an independent predictor of new dementia diagnosis

| Analysis 1: Delirium during 2016 (yes) | Analysis 2: Total number of days with delirium during the year-long study period | Analysis 3: Total number of episodes of delirium during the year-long study period | Analysis 4: Delirium severity according to peak MDAS score during the year-long study period (per point) |
|--------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| 1–5 days                              | > 5 days                                                                         | 1 episode                                                                      | > 1 episode                                                                                        |
| Odds ratio (95% confidence interval, P value) | 8.8 (1.9–41.4), 0.006                                                           | 9.3 (2.0–44.2), 0.005                                                          | 8.4 (0.8–85.0), 0.072                                                                                 |
|                                      | 8.6 (1.8–41.1), 0.007                                                           | 13.9 (1.3–151.0), 0.031                                                        | 1.3 (1.1–1.5), 0.012                                                                                  |
|                                      |                                                                                |                                                                                |                                                                                                    |

Results of consecutive regression analyses exploring delirium variables which independently predict new dementia diagnosis at 1 year after hospital admission (n = 135). Other variables not shown but adjusted for in regression analysis were: age (at recruitment to DECIDE), sex, education, illness severity (peak total APACHE II score), baseline cognition (MMSE score at baseline), co-morbidity (total CIRS-G score recorded on recruitment to DECIDE), frailty (total Clinical Frailty Scale score recorded on recruitment to DECIDE, included as a continuous variable) and time between baseline and follow-up interviews.

**Table 3.** Delirium as an independent predictor of MMSE score at follow-up

| Analysis 1: Delirium during 2016 (yes) | Analysis 2: Total number of days with delirium during the year-long study period | Analysis 3: Total number of episodes of delirium during the year-long study period | Analysis 4: Delirium severity according to peak MDAS score during the year-long study period (per point) |
|--------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| 1–5 days                              | > 5 days                                                                         | 1 episode                                                                      | > 1 episode                                                                                        |
| Coefficient (95% confidence interval, P value) | −1.8 (−3.5--0.2), 0.030                                                           | −1.7 (−3.4--0.1), 0.044                                                        | −5.1 (−8.1--2.1), 0.001                                                                                |
|                                      | 0.9 (−3.6--0.2), 0.362                                                          | 1.5 (−4.7--1.7), 0.031                                                        | −0.4 (−0.6--0.2), 0.001                                                                               |
|                                      | 0.031                                                                           | 0.031                                                                          | 0.001                                                                                              |

Sensitivity analyses showed that excluding the four delirium cases ascertained via consensus panel requiring a third assessor did not alter the overall results.

**Discussion**

In this prospective, population-based cohort study, we have shown for the first time that delirium is associated with a new diagnosis of dementia and cognitive decline, independent of baseline cognition and illness severity. Further, repeated episodes of delirium, more days with delirium and greater severity of delirium are associated with worse cognitive outcomes. Taken together, these findings suggest that increasing grades of delirium exposure (in terms of recurrent episodes, greater severity or longer duration) confer increased risk of dementia.

A strength of DECIDE was the prospective delirium assessments using a standardised approach, including a consensus panel for borderline cases. However, not all participants were seen every day, which might not have captured all days with delirium, particularly given the fluctuating nature of the condition. We mitigated this using review of notes as part of the assessment [23]. Nesting DECIDE within...
an existing, well-characterised cohort with known baseline cognition was also a strength because baseline cognition could be robustly accounted for when quantifying cognitive outcomes after delirium. A limitation was the variation in time that had elapsed between baseline and follow up cognitive assessments. We included a term for this as a potential confounder in our models but it is possible that cognitive function may have deteriorated during this time.

The magnitude and direction of these independent associations are similar to those found in previous studies in which delirium ascertainment was retrospective. The first used data from the original Cognitive Function and Ageing Study cohort (CFAS I) [13], and the second used data from a population-based study of over 85-year olds in Finland [11]. We have not only confirmed the associations, but by accounting for illness severity and baseline cognition and ascertaining delirium prospectively, our results add more detail on the interrelationship between delirium and cognitive outcomes. Additionally, the relationship demonstrated between increasing delirium exposure and cognitive decline supports a dose–response relationship and strengthens evidence for a causal hypothesis [7].

There are substantial clinical implications of this association between grades of delirium exposure and incident dementia and cognitive decline because delirium itself is modifiable, and in some cases preventable [27]. This paves the way for future dementia prevention trials that focus on delirium in order to robustly assess whether delirium intervention in order to robustly assess whether delirium may have contributed to the development and burden of dementia, significant for both individuals and populations.

Supplementary Data: Supplementary data mentioned in the text are available to subscribers in Age and Ageing online.

Acknowledgements: We thank the participants, their families, the general practitioners and their staff, and staff at Newcastle Hospitals NHS Foundation Trust for their co-operation and support. We thank Angela Green, the DECIDE research nurse, for her valuable contribution. We thank our funders and the dementia and neurodegenerative disease research network in Newcastle.

Declaration of Conflicts of Interest: The NIHR Newcastle Biomedical Research Centre (BRC) is a partnership between Newcastle Hospitals NHS Foundation Trust and Newcastle University, funded by the National Institute for Health Research (NIHR). Sarah Richardson is supported by the NIHR Newcastle BRC. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Declaration of Sources of Funding: This work was supported by a Clinical Research Fellowship from the Alzheimer’s Society [grant number 239 (AS-CTF-14-001)] awarded to S.J.R. CFAS II-Newcastle is funded by the UK Medical Research Council [grant number G0601022] and the Alzheimer’s Society [grant number 294].

References

1. Partridge JSL, Martin FC, Harari D, Dhesi JK. The delirium experience: what is the effect on patients, relatives and staff and what can be done to modify this? Int J Geriatr Psychiatry 2013; 28: 804–12.
2. Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing 2006; 35: 350–64.
3. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 2010; 304: 443–51.
4. Salluh JIF, Wang H, Schneider EB et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ 2015; 350: h2538.
5. Jackson JC, Gordon SM, Hart RP, Hopkins RO, Ely EW. The association between delirium and cognitive decline: a review of the empirical literature. Neuropsychol Rev 2004; 14: 87–98.
6. MacLullich AM, Beaghole A, Hall RJ, Meagher DJ. Delirium and long-term cognitive impairment. Int Rev Psychiatry 2009; 21: 30–42.
7. Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface between delirium and dementia in elderly adults. Lancet Neurol 2015; 14: 823–32.
8. Inouye SK, Marcontonio ER, Kosar CM et al. The short-term and long-term relationship between delirium and cognitive trajectory in older surgical patients. Alzheimers Dem 2016; 12: 766–75.
9. Krogseth M, Watne LO, Juliebo V et al. Delirium is a risk factor for further cognitive decline in cognitively impaired hip fracture patients. Arch Gerontol Geriatr 2016; 64: 38–44.
10. Davis DH, Kreisel SH, Muniz Terrera G et al. The epidemiology of delirium: challenges and opportunities for population studies. Am J Geriatr Psychiatry 2013; 21: 1173–89.
11. Davis DH, Muniz Terrera G, Keage H et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain 2012; 135: 2809–16.
12. Tsui A, Kuh D, Richards M, Davis D. Delirium symptoms are associated with decline in cognitive function between ages 53 and 69 years: findings from a British birth cohort study. Alzheimers Dem 2018; 14: 617–22.
13. Davis D, Barnes L, Stephan B et al. The descriptive epidemiology of delirium symptoms in a large population-based cohort study: results from the Medical Research Council cognitive function and ageing study (MRC CFAS). BMC Geriatr 2014; 14: 87.
14. Ehlenbach WJ, Hough CL, Crane PK et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA 2010; 303: 763–70.
15. Wilson RS, Hebert LE, Scherr PA, Dong X, Leurgens SE, Evans DA. Cognitive decline after hospitalization in a community population of older persons. Neurology 2012; 78: 950–6.
16. Mathews SB, Arnold SE, Epperson CN. Hospitalization and cognitive decline: can the nature of the relationship be deciphered? Am J Geriatr Psychiatry 2014; 22: 465–80.

17. Richardson SJ, Davis DHJ, Stephan B et al. Protocol for the delirium and cognitive impact in dementia (DECIDE) study: a nested prospective longitudinal cohort study. BMC Geriatr 2017; 17: 98.

18. Matthews FE, Arthur A, Barnes LE et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the cognitive function and ageing study I and II. Lancet 2013; 382: 1405–12.

19. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington, VA: American Psychiatric Association, 2013.

20. Tieges Z, McGrath A, Hall RJ, Maclullich AM. Abnormal level of arousal as a predictor of delirium and inattention: an exploratory study. Am J Geriatr Psychiatry 2013; 21: 1244–53.

21. Chester JG, Beth Harrington M, Rudolph JL. Serial administration of a modified Richmond agitation and sedation scale for delirium screening. J Hosp Med 2012; 7: 450–3.

22. Breitbart W, Rosenfeld B, Rorh A, Smith MJ, Cohen K, Passik S. The memorial delirium assessment scale. J Pain Symptom Manage 1997; 13: 128–37.

23. Kuhn E, Du X, McGrath K et al. Validation of a consensus method for identifying delirium from hospital records. PLoS One 2014; 9: e111823.

24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–29.

25. Miller MD, Paradis CF, Houck PR et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res 1992; 41: 237–48.

26. Rockwood K, Song X, MacKnight C et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173: 489–95.

27. Siddiqi N, Harrison JK, Clegg A et al. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev 2016. doi: 10.1002/14651858.CD005563.pub3.

Received 21 June 2020; editorial decision 27 September 2020